PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Dapagliflozin - Chronic Kidney Disease
PAD Profile : Dapagliflozin - Chronic Kidney Disease Important
Keywords :
CKD
Brand Names Include :
Forxiga
Important Information :
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
01 June 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends dapagliflozin for treating chronic kidney disease in line with NICE TA 775.
Dapagliflozin will be considered GREEN on the traffic light system.
Key considerations:
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.
Associated BNF Codes
06. Endocrine System
06.01.02. Antidiabetic drugs